28 October 2015
Chemical changes in brain cells caused by disturbances in the body’s day-night cycle may be a key underlying cause of the learning and memory loss associated with Alzheimer’s disease, according to a University of California, Irvine study. The research on mice, led by UCI biomedical engineering professor Gregory Brewer, provides the first evidence that circadian rhythm-altering sleep disruptions similar to jet lag promote memory problems and chemical alterations in the brain.
28 October 2015
Neurocentria Inc., a clinical-stage biopharmaceutical company developing therapeutics to enhance brain function and correct cognitive impairment, announced the successful completion of a human study demonstrating that the company’s lead compound significantly reversed cognitive impairment in subjects 50 to 70 years old. The results have been published in the peer-reviewed Journal of Alzheimer's Disease.
22 October 2015
Benzodiazepines and related drugs are initiated frequently in persons with Alzheimer's disease already before the diagnosis, and their use becomes even more common after the diagnosis, shows a recent study from the University of Eastern Finland. Benzodiazepines and related drugs are used as a sleep medication and for anxiolytic purposes. These drugs were initiated more frequently in persons with Alzheimer's disease than in persons not diagnosed with AD. Compared to persons not diagnosed with AD, it was three times more likely for persons with Alzheimer's disease to initiate benzodiazepine use after the diagnosis, and benzodiazepines were most commonly initiated six months after the diagnosis.
20 October 2015
A new neuroimaging software, Neuroreader, was shown to be as accurate as traditional methods for detecting the slightest changes in brain volume, and does so in a fraction of the time, according to a research study published in the Journal of Alzheimer’s Disease this month. The research validates the software program that can be used for measuring hippocampal volume, a biomarker for detecting Alzheimer’s Disease.
19 October 2015
A new and comprehensive study by investigators at the Celiac Disease Center at Columbia University Medical Center has found that celiac patients are at no increased risk for dementia before or after their diagnosis of celiac disease. “Patients coming to our center have long described ‘brain fog,’ and it appears that gluten can cause cognitive effects in some individuals with and without celiac disease,” said Peter Green, MD, the Phyllis and Ivan Seidenberg Professor of Medicine at Columbia University and the director of the Celiac Disease Center. “However, we didn’t know if these effects have long-term consequences in the form of increased risk of dementia.”
6 October 2015
Researchers led by Deborah Gustafson, PhD, MS, professor of neurology at SUNY Downstate Medical Center, have shown that women with a gene variant (APOEe4 allele) associated with Alzheimer’s disease experience a steeper decline in body mass index (BMI) after age 70 than those women without the version of the gene, whether they go on to develop dementia or not. The finding adds to a body of evidence suggesting that body weight change may aid in the diagnosis and management of Alzheimer's disease.
24 September 2015
Air pollution in Mexico City has detrimental impact on gene associated with Alzheimer’s disease, affecting parents and their children: New study
A new study by researchers at the Universities of Montana, Valle de México, Boise State, and North Carolina, the Centro de Ciencias de la Atmósfera, Universidad Nacional Autónoma de México, Instituto Nacional de Pediatría, and Centro Médico Cozumel heightens concerns over the detrimental impact of air pollution on hippocampal metabolites as early markers of neurodegeneration in young urbanites carrying an allele 4 of the apolipoprotein E gene (APOE). This is associated with the risk for Alzheimer disease (AD) and a susceptibility marker for poor outcome in traumatic brain injury (TBI) recovery.
23 September 2015
FSU Professors Conduct Study Showing Improved Memory for Patients with Mild Cognitive Impairment When Provided with “Nutraceutical Formulation”
Framingham State Professor Ruth Remington, her colleague Tom Shea from UMass Lowell, and members of their research team, have published findings from a study that add to a growing body of evidence that lifestyle modification can help maintain brain power as we age.
18 September 2015
How the brain progresses from mild cognitive impairment (MCI) to Alzheimer's-type dementia has been an enigma for the scientific community. However, a recent study by the team of Dr. Sylvie Belleville, PhD, Director of the Research Centre at the Institut universitaire de gériatrie de Montréal (Montreal Geriatric Institute) and Professor of Psychology at Université de Montréal, has shed light on this progression by showing the typical patterns of the brain's progression to dementia.
15 September 2015
Researchers explore cocoa as novel dietary source for the prevention of cognitive deterioration in Alzheimer’s disease
The potential benefits of dietary cocoa extract and/or its final product in the form of chocolate have been extensively investigated in regard to several aspects of human health. Cocoa extracts contain polyphenols, which are micronutrients that have many health benefits, including reducing age-related cognitive dysfunction and promoting healthy brain aging, among others.